RA'ANANA, Israel, Jan. 22,
2025 /PRNewswire/ -- Inspira Technologies Oxy B.H.N.
Ltd. (NASDAQ: IINN) (NASDAQ: IINNW), ("Inspira Technologies,"
"Inspira" or the "Company"), a groundbreaking respiratory support
technology company, announced that its INSPIRA™ ART100 systems have
been delivered to Glo-Med Networks Inc. ("Glo-Med") and are now
being prepared for their first planned deployment at a leading U.S.
hospital. The deployment will include direct support from Inspira's
team alongside Glo-Med's experts, ensuring a seamless integration
of the revolutionary life-support technology into clinical use.
The delivered INSPIRA™ ART100 systems, as previously announced
on December 16, 2024, will be
distributed to sales targets across hospitals on the U.S. east
coast and distributed to a cardiothoracic surgery division at a
leading New York hospital, ranked
among the top 15 percent of cardiothoracic programs in the U.S.,
with a view to collaborating with such hospital. The Company
believes that the delivery of the INSPIRA™ ART100 to the U.S.
market serves the Company's goal well to introduce physicians and
perfusionists to Inspira's technologies and brand via initial
deployments at leading hospitals.
Designed in collaboration with leading U.S. clinicians, the
INSPIRA™ ART100 cardiopulmonary bypass system revolutionizes
extracorporeal blood circulation by combining cutting-edge
technology with intuitive design to optimize patient care during
crucial times. The INSPIRA™ ART100 is planned to be integrated with
the HYLA™, a continuous blood monitoring technology designed to
potentially detect real-time changes in patient condition. The
HYLA™ is undergoing clinical evaluations at Sheba Hospital, ranked
the 9th in the world by Newsweek™, in patients undergoing
open-heart procedures, in preparation of the Company's planned U.S.
Food and Drug Administration ("FDA") submission of the first
configuration of the HYLA™ in 2025.
Inspira™ Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company
targeting to better the life support and respiratory treatment
arena. The Company is developing a breakthrough Augmented
Respiration Technology (INSPIRA™ ART), a groundbreaking device
poised to revolutionize and potentially replace the $19
billion mechanical ventilation market. With 20 million
intensive care unit patients with acute respiratory failure each
year, many of whom rely on mechanical ventilators, the INSPIRA ART
offers a potential alternative by elevating and stabilizing
decreasing oxygen saturation levels in minutes without a
ventilator, with patients being awake during treatment. The INSPIRA
ART is being designed to include the clip-on HYLA™ blood sensor, a
real-time continuous blood monitoring technology, aiming to alert
physicians of changes in a patient's condition without the need for
intermittent actual blood samples, aiming to support physicians in
making informed decisions.
In May and July 2024,
respectively, the Company's INSPIRA™ ART100 system
has obtained FDA 510(k) clearance for use in CBP procedures, along
with the Israeli AMAR certification for both Extra-Corporeal
Membrane Oxygenation and Cardiopulmonary Bypass procedures.
The Company's other products and technologies, including the
INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the
INSPIRA™ Cardi-ART portable modular device, VORTX™ Oxygen Delivery
System, and HYLA™ blood sensor, are currently being designed and
developed, and have not yet been tested or used in humans nor
approved by any regulatory entity.
For more information, please visit our corporate website
at https://inspira-technologies.com
Forward-Looking Statements
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the prospective
preparation and deployment of the INSPIRA™ ART100 systems,
the prospective distribution lines for the INSPIRA™ ART100
systems, the belief that the delivery of the INSPIRA™ ART100 to the
U.S. market serves the Company's goal well to introduce physicians
and perfusionists to Inspira's technologies and brand via initial
deployments at leading hospitals, the benefits of the INSPIRA™
ART100 , its plan to combine the INSPIRA™ ART100 with the HYLA™,
the expected timing of the planned FDA submission of the first
configuration of the HYLA™. These forward-looking statements and
their implications are based solely on the current expectations of
the Company's management and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Except as
otherwise required by law, the Company undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in the Company's
annual report on Form 20-F for the fiscal year ended December 31, 2023 filed with the U.S. Securities
and Exchange Commission (the "SEC"), which is available on the
SEC's website, www.sec.gov.
Contact: Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
Copyright © 2018-2025 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Logo -
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-technologies-prepares-its-first-life-support-systems-for-deployment-at-a-leading-us-hospital-302357407.html
SOURCE Inspira Technologies
